share_log

We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings

We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings

我們認爲你可以將目光投向深圳海王星英特隆生物技術(HKG: 8329)低迷的收益之外
Simply Wall St ·  04/18 20:26

The market for Shenzhen Neptunus Interlong Bio-technique Company Limited's (HKG:8329) shares didn't move much after it posted weak earnings recently. We think that the softer headline numbers might be getting counterbalanced by some positive underlying factors.

深圳海王英特隆生物技術有限公司(HKG: 8329)在最近公佈疲軟的收益後,其股票市場沒有太大波動。我們認爲,較疲軟的標題數字可能會被一些積極的潛在因素所抵消。

earnings-and-revenue-history
SEHK:8329 Earnings and Revenue History April 19th 2024
SEHK: 8329 2024 年 4 月 19 日的收益和收入記錄

The Impact Of Unusual Items On Profit

不尋常物品對利潤的影響

To properly understand Shenzhen Neptunus Interlong Bio-technique's profit results, we need to consider the CN¥18m expense attributed to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Shenzhen Neptunus Interlong Bio-technique to produce a higher profit next year, all else being equal.

爲了正確了解深圳海王英特隆生物技術的利潤業績,我們需要考慮歸因於不尋常項目的1800萬元人民幣支出。儘管由於不尋常項目而產生的扣除首先令人失望,但有一線希望。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。而且,畢竟,這正是會計術語的含義。假設這些不尋常的支出不會再次出現,因此,我們預計深圳海王星英特隆生物技術在其他條件相同的情況下,明年將產生更高的利潤。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Shenzhen Neptunus Interlong Bio-technique.

注意:我們始終建議投資者檢查資產負債表的實力。點擊此處查看我們對深圳海王星英特隆生物技術的資產負債表分析。

Our Take On Shenzhen Neptunus Interlong Bio-technique's Profit Performance

我們對深圳海王英特隆生物科技盈利表現的看法

Because unusual items detracted from Shenzhen Neptunus Interlong Bio-technique's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Shenzhen Neptunus Interlong Bio-technique's earnings potential is at least as good as it seems, and maybe even better! Unfortunately, though, its earnings per share actually fell back over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. Our analysis shows 4 warning signs for Shenzhen Neptunus Interlong Bio-technique (1 shouldn't be ignored!) and we strongly recommend you look at them before investing.

由於不尋常的項目削弱了深圳海王英特隆生物技術公司去年的收益,你可以爭辯說,我們可以預期本季度的業績會有所改善。正因爲如此,我們認爲深圳海王英特隆生物技術的盈利潛力至少和看起來一樣好,甚至可能更好!但不幸的是,其每股收益實際上在去年有所回落。當然,我們只是在分析其收益時才浮出水面;人們還可以考慮利潤率、預測增長和投資回報率等因素。有鑑於此,如果你想對公司進行更多分析,了解所涉及的風險至關重要。我們的分析顯示,深圳海王英特隆生物技術有4個警告信號(其中一個不容忽視!)我們強烈建議您在投資之前先看看它們。

Today we've zoomed in on a single data point to better understand the nature of Shenzhen Neptunus Interlong Bio-technique's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

今天,我們放大了單個數據點,以更好地了解深圳海王英特隆生物技術有限公司利潤的性質。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。有些人認爲高股本回報率是優質業務的好兆頭。因此,你可能希望看到這份免費收藏的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論